This FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 7, 2022, is between Zogenix, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, a national banking association organized under the laws of the United States of America, as successor trustee (the “Trustee”), paying agent, registrar, and conversion agent, and under and in accordance with the Indenture (as defined below). Capitalized terms used in this Supplemental Indenture without definition have the meanings ascribed to such terms in the Indenture.
W I T N E S S E T H:
WHEREAS, the Company and U.S. Bank National Association, as predecessor to the Trustee entered into an Indenture, dated as of September 28, 2020 (such Indenture, as modified by this Supplemental Indenture, and as the same may be further amended, supplemented or otherwise modified from time to time, the “Indenture”), pursuant to which the Company issued its 2.75% Convertible Senior Notes due 2027 in an aggregate principal amount of $230,000,000 (the “Notes”);
WHEREAS, the Company, UCB S.A., a société anonyme formed under the laws of Belgium (“Parent”), and Zinc Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”) have entered into that certain Agreement and Plan of Merger, dated as of January 18, 2022 (as the same may be further amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), pursuant to which, among other things, Merger Sub will be merged with and into the Company, with the Company continuing as the surviving corporation and as a subsidiary of Parent (the “Merger”);
WHEREAS, in connection with the Merger, each share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), outstanding immediately prior to the effective time of the Merger (the “Effective Time”), subject to certain exceptions set forth in the Merger Agreement, will be automatically converted into the right to receive (i) $26.00, net to the seller in cash, without interest, plus (ii) one non-transferrable contingent value right representing the right to receive a contingent payment of $2.00 (each such contingent payment, a “CVR”), net to the seller in cash, without interest, upon the achievement of the Milestone (as defined in the Merger Agreement) set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as defined in the Merger Agreement);
WHEREAS, Article 6 of the Indenture permits the Company to merge with or into (directly, or indirectly through one or more of its Subsidiaries), subject to the satisfaction of certain conditions set forth therein (the “Merger Conditions”);
WHEREAS, the Company has determined that the Merger satisfies the Merger Conditions;
WHEREAS, the Company has determined the Merger constitutes a “Common Stock Change Event,” a “Business Combination Event,” a “Fundamental Change” and a “Make-Whole Fundamental Change” under the Indenture;